A RANDOMIZED TRIAL COMPARING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT WITH VARICEAL BAND LIGATION IN THE PREVENTION OF REBLEEDING FROM ESOPHAGEAL-VARICES
R. Jalan et al., A RANDOMIZED TRIAL COMPARING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT WITH VARICEAL BAND LIGATION IN THE PREVENTION OF REBLEEDING FROM ESOPHAGEAL-VARICES, Hepatology, 26(5), 1997, pp. 1115-1122
The aim of this study was to compare transjugular intrahepatic portosy
stemic stent-shunt (TIPSS) with variceal band ligation (VBL) in the se
condary prophylaxis of esophageal variceal hemorrhage in patients with
cirrhosis. Fifty-eight patients with cirrhosis who presented with the
first episode of esophageal variceal hemorrhage were randomized to TI
PSS (31) or VBL (27), 24 hours after control of bleeding, Shunt functi
on was assessed after 1 month and then at 6 monthly intervals thereaft
er, VBL was performed weekly until variceal eradication, and then at 3
months, 6 months, and yearly thereafter, Mean follow-up in the TIPSS
group was 15.7 (+/- 10.2) months; in the VBL group, it was 16.8 (+/- 1
0.9) months, Results for rebleeding and mortality were analyzed on an
intention-to-treat basis and using the Kaplan-Meier method, The freque
ncy and the severity of variceal rebleeding was significantly lower in
the TIPSS group (9.8%), compared with the VBL group (51.9%) (P < .000
6), Although mortality rates were not significantly different, 8 of th
e patients who rebled in the VBL group required TIPSS therapy for unco
ntrolled bleeding. No significant differences were found in the freque
ncy of other complications such as encephalopathy and sepsis. Patients
in the VBL group required significantly greater time in the intensive
care unit during the period of this study (< 0.03), The total direct
cost of treatment incurred was pound 1,373 ($2,200) per patient, the c
ost being less in the patients treated with TIPSS compared with VBL. T
he results of this study show that TIPSS is superior to VBL for the se
condary prophylaxis of variceal hemorrhage in patients with cirrhosis.